Valuation: Zai Lab Limited

Market Cap 2.15B 1.88B 1.73B 1.61B 3.05B 205B 3.1B 20.72B 8.05B 101B 8.06B 7.89B 346B P/E 2026 *
-8.63x
P/E 2027 * -10.3x
Enterprise Value 1.71B 1.49B 1.37B 1.28B 2.42B 162B 2.46B 16.45B 6.39B 79.8B 6.4B 6.26B 275B EV / Sales 2026 *
3.8x
EV / Sales 2027 * 2.96x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 week+7.05%
Current month+1.21%
1 month+14.38%
3 months-6.18%
6 months+12.84%
Current year+12.08%
1 week 15.6
Extreme 15.6
17.1
1 month 13.7
Extreme 13.7
17.1
3 years 12.8
Extreme 12.8
38.8
5 years 12.8
Extreme 12.8
148
Manager TitleAgeSince
Chief Executive Officer 61 31/03/2014
Director of Finance/CFO 58 06/07/2023
President 62 30/11/2022
Director TitleAgeSince
Chairman 61 31/03/2014
Director/Board Member 83 31/12/2016
Director/Board Member 75 31/12/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+7.05%-46.13%-36.74% 2.15B
+4.73%+3.38%+19.53%-8.85% 66.56B
-1.93%+0.39%+53.64%+224.54% 56.51B
+1.07%+42.10%+42.10%+42.10% 42.98B
+0.99%+6.62%-50.39%-54.85% 40.46B
+3.04%+0.04%+62.66%-24.40% 31.91B
+10.01%+18.57%+161.59%-35.44% 31.65B
+2.68%+2.73%+70.72%+85.52% 23.35B
+0.17%+9.87%+6.54%+186.95% 19.46B
-0.13%+2.75%+66.32%+128.53% 17.18B
Average +2.29%+8.76%+38.66%+50.73% 36.67B
Weighted average by Cap. +2.33%+7.31%+42.25%+52.84%

Financials

2026 *2027 *
Net sales 449M 392M 360M 336M 637M 42.72B 647M 4.33B 1.68B 21B 1.68B 1.65B 72.36B 596M 521M 478M 446M 846M 56.71B 859M 5.74B 2.23B 27.87B 2.24B 2.19B 96.05B
Net income -241M -211M -194M -180M -342M -22.94B -347M -2.32B -903M -11.27B -904M -885M -38.85B -156M -137M -126M -117M -222M -14.9B -226M -1.51B -587M -7.32B -587M -575M -25.24B
Net Debt -443M -387M -356M -332M -629M -42.19B -639M -4.27B -1.66B -20.74B -1.66B -1.63B -71.47B -387M -338M -311M -290M -550M -36.87B -558M -3.73B -1.45B -18.12B -1.45B -1.42B -62.45B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
03/07/26 €16.70 0.00%
02/07/26 €16.70 -2.34%
01/07/26 €17.10 +3.64%
30/06/26 €16.50 +3.77%
29/06/26 €15.90 +1.92%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.12USD
Average target price
33.30USD
Spread / Average Target
+74.18%

Quarterly revenue - Rate of surprise